1762.Tw
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
The company's capital structure shows a debt-to-equity ratio of 0.26, indicating a relatively conservative leverage position. However, the company's liquidity is assessed as medium, and its free cash flow is negative at -129,569,000 TWD, suggesting potential short-term liquidity constraints. The current ratio of 2.97 implies the company has sufficient current assets to cover its current liabilities.
Profitability metrics are concerning, with a return on equity of -7.9% and a return on assets of -5.65%, both significantly below industry norms. The company reported a net loss of 243,847,000 TWD, and its operating income was also negative at 319,406,000 TWD, indicating operational inefficiencies or declining sales. Gross profit was negative at -8,864,000 TWD, further highlighting cost management issues.
The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification in its revenue streams. This could expose the company to higher business risk if a key market or product line underperforms.
Looking ahead, the company's growth trajectory is uncertain. Analysts have assigned a mean recommendation of 3.00, which is a "Hold" rating, with no strong buy or buy ratings. The last actual EPS was -4.39 TWD, while the mean EPS estimate is 0.45 TWD, indicating a potential recovery in earnings. However, the company's capital expenditure of -62,334,000 TWD suggests a reduction in investment in growth initiatives.
The company's risk profile includes medium liquidity risk and low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential cash flow challenges. The company's dilution potential is low, and no adjustments have been applied to its valuation metrics.
Recent events, including filings and transcripts, are not detailed in the available data, but the company's financial performance and analyst ratings suggest a cautious outlook. The absence of strong buy or buy ratings from analysts indicates a lack of confidence in the company's near-term prospects.
- The company is operating at a net loss with negative operating and gross profits, indicating significant operational challenges.
- The company's liquidity is medium, and its free cash flow is negative, suggesting potential short-term financial constraints.
- The company's return on equity and return on assets are both negative, significantly below industry norms.
- Analysts have assigned a "Hold" rating to the company, with no strong buy or buy ratings, indicating a cautious outlook.
- The company's capital expenditure is negative, suggesting a reduction in investment in growth initiatives.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,45 |
| Revenue | —no estimate | —no estimate | 1,4B TWD |
| Operating income | —no estimate | —no estimate | 31,0M TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 1762.TW Market data — financials · 2026-05-26
- Chunghwa Chemical Synthesis & Biotech Co Ltd Market data — analyst estimates · 2026-05-26